X-linked Hypophosphatemia

X-linked Hypophosphatemia Disease Monitoring Program

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Calcitriol Monotherapy for X-Linked Hypophosphatemia

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

Phosphorus-31 Spectroscopy in Phosphate Diabetes

Expanded Access to Burosumab

Registry for Patients With X-Linked Hypophosphatemia

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

A Study of KRN23 in X-linked Hypophosphatemia

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls

Foot Disorders in X-linked Hypophosphatemia

Examining the Effect of Burosumab on Muscle Function